Age of onset as a moderator of cognitive decline in pediatric-onset multiple sclerosis

Banafsheh Hosseini1, David B Flora1, Brenda L Banwell2

  • 11Department of Psychology,York University,Toronto,Canada.

Insights

Younger age at disease onset in pediatric multiple sclerosis (MS) increases the risk of cognitive decline. Cognitive reserve did not appear to protect against these deficits in children and adolescents with MS.

Area of Science:

  • Neuroscience
  • Pediatric Neurology
  • Cognitive Psychology

Background:

  • Cognitive impairment is a significant concern in pediatric-onset multiple sclerosis (MS).
  • Understanding factors influencing cognitive development in these young patients is crucial for early intervention and management.
  • Longitudinal studies are needed to track cognitive changes from childhood through adolescence.

Purpose of the Study:

  • To investigate the impact of age at disease onset on cognitive maturation in pediatric MS.
  • To examine the role of cognitive reserve (proxies: baseline IQ, social status) in moderating cognitive trajectories.
  • To analyze longitudinal cognitive data using growth curve modeling.

Main Methods:

  • Serial neuropsychological evaluations were conducted on 35 individuals with pediatric-onset MS.
  • Growth curve modeling analyzed changes in Trail Making Test-Part B (TMT-B) and Symbol Digit Modalities Test (SDMT).
  • Age at onset, baseline Full Scale IQ, and parental social status were assessed as potential moderators.

Main Results:

  • Younger age at disease onset was significantly associated with cognitive decline on both TMT-B and SDMT.
  • Baseline IQ and parental social status did not moderate the rate of cognitive change.
  • Cognitive reserve proxies did not offer protection against cognitive decline progression.

Conclusions:

  • Early-onset pediatric MS, particularly with younger age at onset, heightens vulnerability to cognitive deficits.
  • Cognitive reserve may not buffer against cognitive decline in pediatric MS patients.
  • Regular cognitive evaluations are recommended for young MS patients to monitor maturation and detect potential deficits.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
16
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.4K
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
19
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405
Cognitive Development During Adolescence01:18

Cognitive Development During Adolescence

During adolescence, individuals experience significant cognitive development that enhances their understanding of others' emotions and thoughts, known as cognitive empathy. This period is marked by an increased ability to adapt to others' perspectives and a more nuanced understanding of others' mental states, a skill that is foundational for social problem-solving and conflict avoidance. The development of cognitive empathy relies heavily on the theory of mind — the...
1.0K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K